Keros Therapeutics (NASDAQ:KROS) Stock Bumped Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Several other analysts have also weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Leerink Partners lowered their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Performance

Shares of KROS opened at $11.95 on Friday. The firm has a market cap of $236.97 million, a P/E ratio of -3.23 and a beta of 1.12. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55. The firm’s 50-day simple moving average is $11.10 and its 200 day simple moving average is $11.05.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics announced that its board has approved a stock buyback plan on Wednesday, September 9th that allows the company to buy back $5.00 million in shares. This buyback authorization allows the company to reacquire up to 2.3% of its shares through open market purchases. Share buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 5,343 shares of company stock worth $54,985. Corporate insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KROS. BlackRock Inc. bought a new stake in Keros Therapeutics during the 2nd quarter worth approximately $29,898,000. Nantahala Capital Management LLC bought a new stake in Keros Therapeutics in the 2nd quarter worth approximately $15,091,483. Dimensional Fund Advisors LP grew its holdings in shares of Keros Therapeutics by 453.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after purchasing an additional 263,347 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Keros Therapeutics in the second quarter worth about $2,641,000. Finally, Man Group plc purchased a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $1,664,000. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. These biological pathways influence blood-cell production, bone health, muscle growth and cardiovascular function, and may play a role in several serious diseases.

The company’s investigational portfolio has included elritercept (KER-050), an engineered ligand trap designed to enhance red blood cell production and address anemia associated with conditions such as myelodysplastic syndromes and myelofibrosis.